首页> 美国卫生研究院文献>Molecular Cancer >Epigenetics in ovarian cancer: premise properties and perspectives
【2h】

Epigenetics in ovarian cancer: premise properties and perspectives

机译:卵巢癌的表观遗传学:前提性质和观点

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Malignant ovarian tumors bear the highest mortality rate among all gynecological cancers. Both late tumor diagnosis and tolerance to available chemical therapy increase patient mortality. Therefore, it is both urgent and important to identify biomarkers facilitating early identification and novel agents preventing recurrence. Accumulating evidence demonstrates that epigenetic aberrations (particularly histone modifications) are crucial in tumor initiation and development. Histone acetylation and methylation are respectively regulated by acetyltransferases-deacetylases and methyltransferases-demethylases, both of which are implicated in ovarian cancer pathogenesis. In this review, we summarize the most recent discoveries pertaining to ovarian cancer development arising from the imbalance of histone acetylation and methylation, and provide insight into novel therapeutic interventions for the treatment of ovarian carcinoma.
机译:在所有妇科癌症中,恶性卵巢肿瘤的死亡率最高。晚期肿瘤诊断和对可用化学疗法的耐受性均增加患者死亡率。因此,鉴定有助于早期识别的生物标志物和防止复发的新型药物既紧急又重要。越来越多的证据表明,表观遗传畸变(尤其是组蛋白修饰)在肿瘤的发生和发展中至关重要。组蛋白的乙酰化和甲基化分别受乙酰转移酶-去乙酰化酶和甲基转移酶-去甲基化酶的调节,这两者均与卵巢癌的发病机理有关。在这篇综述中,我们总结了由组蛋白乙酰化和甲基化的失衡引起的与卵巢癌发展有关的最新发现,并提供了对卵巢癌治疗新疗法的见解。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号